POLXF Financials 07/16/2014 06:25:24 Polydex Phar
Post# of 4
Posted On: 07/16/2014 7:25:21 AM
POLXF Financials 07/16/2014 06:25:24
Polydex Pharmaceuticals Ltd.
Period Ending Jan 31, 2010
Total Revenue 4,481
Cost of Revenue 4,573
Gross Profit (92)
Operating Expenses
Research and Development 4
Sales, General and Admin. 966
Non-Recurring Items 915
Other 17
Operating Income (1,994)
Income From Continuing Operations
Add'l Income/Expense Items (96)
Earnings Before Interest and Tax (2,090)
Interest Expense 55
Earnings Before Tax (2,145)
Income Tax -
Minority Interest -
Equity Earnings Unconsolidated Subsidiary -
Net Income Cont. Operations (2,145)
Non Recurring Events
Discontinued Operations -
Extraordinary Items -
Effect of Accounting Changes -
Other Items -
Net Income (2,145)
Preferred Stock and Other Adjustments -
Net Income Applicable to Common Shareholders (2,145)
Polydex Pharmaceuticals Ltd.
Period Ending Jan 31, 2010
Total Revenue 4,481
Cost of Revenue 4,573
Gross Profit (92)
Operating Expenses
Research and Development 4
Sales, General and Admin. 966
Non-Recurring Items 915
Other 17
Operating Income (1,994)
Income From Continuing Operations
Add'l Income/Expense Items (96)
Earnings Before Interest and Tax (2,090)
Interest Expense 55
Earnings Before Tax (2,145)
Income Tax -
Minority Interest -
Equity Earnings Unconsolidated Subsidiary -
Net Income Cont. Operations (2,145)
Non Recurring Events
Discontinued Operations -
Extraordinary Items -
Effect of Accounting Changes -
Other Items -
Net Income (2,145)
Preferred Stock and Other Adjustments -
Net Income Applicable to Common Shareholders (2,145)
(0)
(0)Polydex Pharm Ltd (POLXF) Stock Research Links
Scroll down for more posts ▼